The non-steroidal anti-inflammatory drug (NSAID) compounds in Achelios’ pipeline have existed in the worldwide marketplace for some time, and are no longer protected by patents. However, the Company’s ACHETOGEL™ technology offers a substantial exclusivity position due to Achelios’ intellectual property. Through a combination of acquired patent rights and issued and newly submitted patent applications, Achelios Therapeutics has secured patent protection for TOPOFEN™ until at least 2032, with the opportunity to extend that further with careful life-cycle management. Achelios’ patent portfolio is organized around a tiered structure:
- Base Tier: Achelios’ drug delivery system patents serve as the backbone of their value creation strategy. These patents relate to aqueous pharmaceutical compositions for the transdermal administration of NSAIDs to a patient, and encompass different transdermal application vehicles such as gels, liquids, and patches.
- Middle Tier: Achelios’ composition of formulation patent relates generally to a non-irritating topical analgesic for the treatment of various forms of pains such as nociceptive pain, inflammatory pain, pathological pain, and migraine pain.
- Top Tier: Achelios’ method-of-use patent for topical ketoprofen, as well as other NSAIDs, for the indication of acute migraine.
The Company has recently completed and filed composition of formulation patents for various other NSAIDs. Trademarks include:
- ACHETOGEL – 86/446,999
- TOPOSPRAY – 86/447,012
- TOPOFEN – 86/447,026